Signals, Powered By EquityPandit
Syngene International, the research arm of Biocon has entered into a multi-year research and development (R&D) pact, with British drug major GSK, to provide drug discovery services to the latter.
The agreement will have a focus on speeding up the discovery of new drug candidates, using Syngene’s discovery services platforms. Under the agreement, Syngene will set-up a customized discovery research laboratory to support projects across several therapeutic areas.
The total cash consideration for the agreement was not disclosed. Furthermore, Syngene stated, “A team of Syngene scientists, will work closely with GSK’s global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world’s most pressing healthcare needs.”
